Electrical Stimulation for Migraine

N/A

Recruiting

Led By Thomas Perreault, DPT

Research Sponsored by Thomas W. Perreault, PT

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will look at whether intramuscular electrical stimulation can reduce frequency and intensity of headaches in people with chronic migraine. Participants will be their own control and track their headaches before and after treatment.

Who is the study for?

This trial is for individuals who have been experiencing chronic migraines for at least six months. Participants should have trigger points in specific neck muscles that, when stimulated, reproduce their headache symptoms. It's not suitable for those who don't meet the International Headache Society criteria or lack these particular trigger points.

What is being tested?

The study tests if intramuscular electrical stimulation can reduce headache frequency and intensity in migraine sufferers. Patients will use dry needling combined with electrical currents on muscle trigger points and track their headaches using an electronic diary.

What are the potential side effects?

Potential side effects may include discomfort at needle insertion sites, muscle soreness after treatment, minor bleeding or bruising where needles are placed, and temporary increase in headache pain following the procedure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Headache Frequency

Secondary study objectives

Headache Impact Test-6 (HIT-6)

Migraine Disability Assessment Test (MIDAS)

Other study objectives

Numeric Pain Rating Scale

Pressure pain threshold

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Experimental Treatment

Group I: 7 week baselineExperimental Treatment1 Intervention

Randomization to the fourth tier will include 7 weeks (49 days) of baseline measure, followed by 5 weeks of treatment and symptom monitoring

Group II: 6 week baselineExperimental Treatment1 Intervention

Randomization to the third tier will include 6 weeks (42 days) of baseline measures, followed by 5 weeks of treatment and symptom monitoring (phase B)

Group III: 5 week baselineExperimental Treatment1 Intervention

Randomization to the second tier will include 5 weeks (35 days) of baseline measures (phase A), followed by 5 weeks of treatment and symptom monitoring (phase B)

Group IV: 4 week baselineExperimental Treatment1 Intervention

Randomization to the first tier will include 4 weeks (28 days) of baseline measures (phase A), followed by 5 weeks of treatment and symptom monitoring (phase B)

Do I qualify?Apply below to find out